Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 3:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–19 of 19 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Fibrocystic Disease of Breast Clear all
Not listed No phase listed Observational

Women At Risk: The High Risk Breast Cancer Program

NCT01034891
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
New York Presbyterian Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1991
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 17, 2009 · Synced Jul 23, 2026, 3:55 AM EDT
Terminated Phase 2 Interventional

Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer

NCT03979508
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Breast Ductal Carcinoma In Situ, Breast Fibrocystic Change, Breast Lobular Carcinoma In Situ, Invasive Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
Interventions
Abemaciclib, Therapeutic Conventional Surgery
Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 11, 2025 · Synced Jul 23, 2026, 3:55 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions

NCT01931644
View directory record Official record
Conditions
All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis, Asthma, Atopic Dermatitis Eczema, Beta Thalassemia, Bipolar Disorder, Breast Cancer, Celiac Disease, Cervical Cancer, Chronic Inflammatory Demyelinating Polyneuropathy, Chronic Kidney Diseases, Chronic Obstructive Pulmonary Disease, Colon Cancer, Colorectal Cancer, Crohn's Disease, Cystic Fibrosis, Depression, Diabetes Mellitus, Duchenne Muscular Dystrophy, Endometriosis, Epilepsy, Facioscapulohumeral Muscular Dystrophy, G6PD Deficiency, General Anxiety Disorder, Hepatitis B, Hereditary Hemorrhagic Telangiectasia, HIV/AIDS, Human Papilloma Virus, Huntington's Disease, Idiopathic Thrombocytopenic Purpura, Insomnia, Kidney Cancer, Leukemia, Lung Cancer, Lupus Nephritis, Lymphoma, Melanoma, Multiple Myeloma, Multiple Sclerosis, Myositis, Myotonic Dystrophy, Ovarian Cancer, Pancreatic Cancer, Parkinson's Disease, Polycystic Kidney Diseases, Prostate Cancer, Psoriasis, Psoriatic Arthritis, Rosacea, Scleroderma, Sickle Cell Anemia, Sickle Cell Trait, Sjogren's Syndrome, Skin Cancer, Spinal Muscular Atrophy, Systemic Lupus Erythematosus, Thrombotic Thrombocytopenic Purpura, Trisomy 21, Ulcerative Colitis
Interventions
Not listed
Lead sponsor
Sanguine Biosciences
Industry
Eligibility
18 Years to 100 Years
Enrollment
17,667 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Jul 23, 2026, 3:55 AM EDT
Completed No phase listed Observational

Studying Blood and Tumor Tissue Samples in Women With Invasive Breast Cancer, Ductal or Lobular Carcinoma in Situ, or Benign Breast Disease

NCT00898508
View directory record Official record
Conditions
Breast Cancer
Interventions
gene expression analysis, mutation analysis, proteomic profiling, reverse transcriptase-polymerase chain reaction, fluorescent antibody technique, immunohistochemistry staining method, laboratory biomarker analysis, liquid chromatography, mass spectrometry, medical chart review, quality-of-life assessment
Genetic · Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
20 Years and older · Female only
Enrollment
563 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2019
U.S. locations
3
States / cities
Beverly Hills, California • Duarte, California • Pasadena, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2025 · Synced Jul 23, 2026, 3:55 AM EDT
Completed No phase listed Observational

X-Ray Mammography Standard of Care Protocol

NCT01052740
View directory record Official record
Conditions
Breast Cancer, Invasive Carcinoma, In Situ Carcinoma, Fibrocystic Changes, Atypical Ductal Hyperplasia
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 100 Years · Female only
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 23, 2026, 3:55 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

A Multilevel Approach to Connecting Underrepresented Populations to Clinical Trials

NCT05655494
View directory record Official record
Conditions
Cancer
Interventions
Stand-alone Research Portal, Portal with Virtual Community Health Educator (vCHE)
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 100 Years
Enrollment
350 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
3
States / cities
Gainesville, Florida • Jacksonville, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Jul 23, 2026, 3:55 AM EDT
Completed No phase listed Observational

Cystic Breast Masses by Contrast Enhanced Ultrasound (CEUS)

NCT02887937
View directory record Official record
Conditions
Breast Cancer
Interventions
Definity
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 14, 2018 · Synced Jul 23, 2026, 3:55 AM EDT
Completed Early Phase 1 Interventional

A Comparison of Breast Tomosynthesis Mammography and Conventional Breast Imaging in the Characterization of Breast Masses

NCT00826488
View directory record Official record
Conditions
Fibrocystic Disease of Breast, Breast Cancer
Interventions
Digital Breast Tomosynthesis
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
35 Years to 80 Years · Female only
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 1, 2015 · Synced Jul 23, 2026, 3:55 AM EDT
Completed Not applicable Interventional Results available

Comparison of MRI and Molecular Breast Imaging in Breast Diagnostic Evaluation

NCT00591864
View directory record Official record
Conditions
Breast Cancer
Interventions
Molecular Breast Imaging
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
25 Years and older · Female only
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 8, 2014 · Synced Jul 23, 2026, 3:55 AM EDT
Completed Not applicable Interventional

A Randomized Double-blind, Placebo Controlled, Multi-center Study to Evaluate the Safety, Tolerability and Potential Effects of the Dietary Supplement Violet™ Molecular Iodine (I2) on Breast Health in Women With Cyclic Breast Discomfort and Tenderness

NCT02676336
View directory record Official record
Conditions
Fibrocystic Breast Condition (FBC)
Interventions
Violet™ Molecular Iodine (I2), Placebo
Dietary Supplement · Other
Lead sponsor
BioPharmX, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jul 9, 2018 · Synced Jul 23, 2026, 3:55 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

VITamin D and OmegA-3 TriaL: Effects on Mammographic Density and Breast Tissue

NCT02239874
View directory record Official record
Conditions
Benign Breast Disease
Interventions
Vitamin D and fish oil placebo, Fish oil and vitamin D placebo, Vitamin D placebo and fish oil placebo, Vitamin D and fish oil
Dietary Supplement
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
55 Years to 67 Years · Female only
Enrollment
3,894 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 6, 2022 · Synced Jul 23, 2026, 3:55 AM EDT
Completed Phase 2 Interventional Results available

Study of Docosahexaenoic Acid (DHA) in Triple Negative Breast Cancer Survivors

NCT01849250
View directory record Official record
Conditions
Benign Breast Neoplasm, Ductal Breast Carcinoma In Situ, Invasive Breast Carcinoma, Lobular Breast Carcinoma In Situ, Paget Disease of the Breast, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
Docosahexaenoic Acid, Placebo
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
4
States / cities
Boston, Massachusetts • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 27, 2021 · Synced Jul 23, 2026, 3:55 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

An Open-Label, MultiCenter Evaluation of the Use of Topically Administered FP1198 in Subjects With Pain Associated With Cyclic Mastalgia

NCT01105793
View directory record Official record
Conditions
Moderate to Severe Cyclic Mastalgia
Interventions
Danazol
Drug
Lead sponsor
FemmePharma Global Healthcare, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
4
States / cities
San Diego, California • Denver, Colorado • Lexington, Kentucky + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2011 · Synced Jul 23, 2026, 3:55 AM EDT
Completed No phase listed Observational

Genetics of Mammographic Appearances and Patterns (The GenMap Study)

NCT01160510
View directory record Official record
Conditions
Benign Breast Disease
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years · Female only
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Mar 11, 2020 · Synced Jul 23, 2026, 3:55 AM EDT
Recruiting No phase listed Observational

ARPKD Database Study

NCT01401998
View directory record Official record
Conditions
Hepato/Renal Fibrocystic Disease, Autosomal Recessive Polycystic Kidney Disease, Joubert Syndrome, Bardet Biedl Syndrome, Meckel-Gruber Syndrome, Congenital Hepatic Fibrosis, Caroli Syndrome, Oro-Facial-Digital Syndrome Type I, Nephronophthisis, Glomerulocystic Kidney Disease
Interventions
Not listed
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Up to 18 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2030
U.S. locations
6
States / cities
Washington D.C., District of Columbia • Atlanta, Georgia • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Jul 23, 2026, 3:55 AM EDT
Terminated No phase listed Observational

Nipple Secretion Samples in Detecting Breast Cancer in Patients and Healthy Participants Undergoing Breast Cancer Screening, Breast Diagnostic Studies, or Treatment for Benign Breast Disease

NCT00813878
View directory record Official record
Conditions
Breast Cancer
Interventions
protein analysis, protein expression analysis, proteomic profiling, diagnostic laboratory biomarker analysis, immunohistochemistry staining method, liquid chromatography, mass spectrometry, fine-needle aspiration, needle biopsy, radiomammography
Genetic · Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2012
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Oct 12, 2017 · Synced Jul 23, 2026, 3:55 AM EDT
Not listed Phase 3 Interventional

Study for Treatment of Moderate or Severe, Periodic, "Cyclic", Breast Pain

NCT00237523
View directory record Official record
Conditions
Fibrocystic Disease of Breast, Fibrocystic Changes of Breast, Fibrocystic Mastopathy, Pain
Interventions
IoGen (molecular iodine)
Drug
Lead sponsor
Symbollon Pharmaceuticals
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
39
States / cities
Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2007 · Synced Jul 23, 2026, 3:55 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Nuclear Morphology of Breast Cells in Ductal Lavage

NCT00259597
View directory record Official record
Conditions
Benign Breast Disease
Interventions
breast ductal lavage
Procedure
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older · Female only
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 19, 2012 · Synced Jul 23, 2026, 3:55 AM EDT
Completed Phase 2 Interventional

A Study of Topical Danazol for the Treatment of Pain Associated With Fibrocystic Breast Disease

NCT00744276
View directory record Official record
Conditions
Fibrocystic Disease of Breast
Interventions
danazol, Placebo
Drug
Lead sponsor
FemmePharma Global Healthcare, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
30
States / cities
Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 26 more
Source: ClinicalTrials.gov public record
Updated May 26, 2010 · Synced Jul 23, 2026, 3:55 AM EDT